Sanofi Shares Fall 2% Following Morgan Stanley Downgrade
Sanofi's stock declines in early afternoon, affected by a downgrade issued on the same day by Morgan Stanley. The movement occurs in a Parisian market that is also trending downward, with the CAC 40 losing 0.76% during the session.
Morgan Stanley Shifts to Neutral and Lowers Target to €90
Sanofi's stock drops 2.08% to €78.16, after Morgan Stanley downgraded its recommendation from 'overweight' to 'market-weight', while also lowering its price target from €95 to €90. At the current price, the new target offers a theoretical potential of about 15%. The session follows a medium-term unfavorable trend: the stock has lost 20.18% over a year and 3.6% over three months. The decline comes about ten days after a solid quarterly release, highlighted by a revenue increase of 13.6% at constant exchange rates and a 14% rise in EPS. During this release, the group confirmed expected sales growth for 2025 at a high single-digit percentage at CER, and anticipated a rebound in business EPS at a low double-digit percentage.
Price Below Lower Bollinger Band, Under MM200
At €78.16, Sanofi is trading below its 200-day moving average (€82.43) and its MM50 (€79.52), confirming the bearish pressure that began at the end of April. The price has moved below the lower Bollinger band set at €79.47, indicating a technical oversold condition. The RSI at 48 remains neutral, with no marked exhaustion signals. The identified support at €76.12 is about 2.6% below the current price. In the background, the ECB maintained its key interest rates unchanged on April 30 while signaling a simultaneous intensification of risks on inflation and growth, a macro context that weighs on the entire European stock market. The next key event on the financial calendar is the publication of the second quarter 2026 results, scheduled for July 30.
